Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Atopic Dermatitis Market Snapshot: The Next Multi-Billion Dollar Opportunity

Executive Summary

New treatments for atopic dermatitis – including the first biologic medicine for the disease – could launch next year, fueling substantial growth in a therapy area where there have been few advances. Payers, however, will be keeping an eye on the cost.


Related Content

MatriSys Focuses On ‘Good Microbe’ Approach To Dermatology, Maybe Skin Cancer Too
Tech Transfer Roundup: ProQR Partners With Foundation Fighting Blindness On Rare Vision-Loss Disorder
AAD Roundup: More Data Emerges In Atopic Dermatitis, But Dupixent Maintains Big Lead
JAK Inhibitors Have Dupixent In Their Sights For Atopic Dermatitis
Dermira Takes Roche's Lebrikizumab With Best-In-Class Ambitions
'Potential Blockbuster' Dupixent Set For EU Eczema OK
Sanofi/Regeneron Choose Access Over Price With Dupixent Launch
Pfizer Assembling New Commercial Team For Move Into Dermatology
AstraZeneca Hands LEO Dermatology Potential
FDA Approves Boxed Warning On Cancer Risk For Elidel And Protopic


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts